Cargando…

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

INTRODUCTION: Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rouland, Alexia, Bouillet, Benjamin, Legris, Pauline, Simoneau, Isabelle, Petit, Jean-Michel, Vergès, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872904/ https://www.ncbi.nlm.nih.gov/pubmed/33574715 http://dx.doi.org/10.2147/CPAA.S278978

Ejemplares similares

Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients
por: Vergès, Bruno, et al.
Publicado: (2020)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes
por: Denimal, Damien, et al.
Publicado: (2023)

Case Report: Giant insulinoma, a very rare tumor causing hypoglycemia
por: Tarris, Georges, et al.
Publicado: (2023)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review
por: Rouland, Alexia, et al.
Publicado: (2022)

Diabetes is not associated with COVID-19-related mortality in older institutionalized people
por: Legris, Pauline, et al.
Publicado: (2021)

Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes
por: Denimal, Damien, et al.
Publicado: (2023)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
por: Oziel-Taieb, Sandrine, et al.
Publicado: (2022)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Pasireotide: A Novel Treatment for Tumor-Induced Hypoglycemia Due to Insulinoma and Non-Islet Cell Tumor Hypoglycemia
por: Siddiqui, Mahwash, et al.
Publicado: (2020)

HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control
por: Denimal, Damien, et al.
Publicado: (2022)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SUN-319 Failure Of Pasireotide To Control Hypoglycemia In A Men-1 Patient With Metastatic Insulinoma
por: de Almeida, Tobias, et al.
Publicado: (2019)

Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion
por: Omi, Tsubasa, et al.
Publicado: (2016)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Effect of Naloxon on Counter Insulin Hormone Secretion in Insulin-Induced Hypoglycemia
por: Ju, Yeong Shil, et al.
Publicado: (1987)

Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia
por: Gordon, Murray B, et al.
Publicado: (2017)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature
por: Husni, Hasan, et al.
Publicado: (2022)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial
por: Paris, Justine, et al.
Publicado: (2023)

Identification of an oral microbiota signature associated with an impaired orosensory perception of lipids in insulin-resistant patients
por: Besnard, Philippe, et al.
Publicado: (2020)

Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study
por: Chéreau, Elisabeth, et al.
Publicado: (2016)

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study
por: Benamouzig, Robert, et al.
Publicado: (2018)

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities
por: Denimal, Damien, et al.
Publicado: (2022)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
por: Mondin, Alessandro, et al.
Publicado: (2022)

Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line
por: Gentilin, E., et al.
Publicado: (2023)

Successful Medical Treatment of Adult Nesidioblastosis With Pasireotide over 3 Years: A Case Report
por: Schwetz, Verena, et al.
Publicado: (2016)

Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy
por: Jerkins, Terri W., et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cucltsp2uf2nfbl4t7uk1mtifp